Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹20,201 Cr
Revenue (TTM)
₹6,672 Cr
Net Profit (TTM)
₹582 Cr
ROE
11.6 %
ROCE
13.5 %
P/E Ratio
34.6
P/B Ratio
3.9
Industry P/E
37.67
EV/EBITDA
20.3
Div. Yield
1.1 %
Debt to Equity
0.2
Book Value
₹264.1
EPS
₹29.7
Face value
2
Shares outstanding
196,563,124
CFO
₹6,480.57 Cr
EBITDA
₹9,302.81 Cr
Net Profit
₹6,116.57 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Alembic Pharma
| -3.8 | 2.6 | 21.1 | 4.4 | 13.4 | 1.6 | 2.8 |
|
BSE Healthcare
| 0.3 | 2.9 | 9.7 | 16.8 | 26.1 | 22.0 | 9.9 |
|
BSE Mid Cap
| 1.4 | 3.0 | 13.4 | -1.9 | 27.2 | 28.9 | 15.6 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Alembic Pharma
| 39.2 | 32.6 | -28.6 | -23.1 | 87.7 | -2.6 | 12.9 |
|
BSE Mid Cap
| 25.8 | 45.5 | 1.4 | 39.2 | 19.9 | -3.0 | -13.3 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Alembic Pharma
|
1,025.4 | 20,200.8 | 6,672.1 | 582.0 | 10.9 | 11.6 | 34.6 | 3.9 |
| 1,063.8 | 40,580.8 | 1,197.6 | 264.8 | 24.9 | 14.6 | 151.5 | 23.7 | |
| 2,204.8 | 62,946.3 | 13,321.7 | 1,047.1 | 14.0 | 14.6 | 60.1 | 7.1 | |
| 499.7 | 12,120.1 | 4,481.6 | 501.5 | 16.1 | 13.4 | 24.2 | 3.3 | |
| 1,194.5 | 18,989.5 | 7,234.5 | 836.8 | 11.1 | 7.9 | 22.6 | 3.0 | |
| 822.6 | 44,458.7 | 5,554.0 | 354.4 | 11.3 | 8.3 | 124.1 | 10.0 | |
| 1,021.4 | 18,160.0 | 4,429.5 | 1,883.4 | 44.3 | 25.6 | 9.6 | 2.4 | |
| 214.9 | 28,406.0 | 9,151.2 | 91.1 | 6.9 | 1.1 | 311.7 | 3.5 | |
| 667.8 | 26,924.4 | 3,642.4 | 496.2 | 16.6 | 11.2 | 54.3 | 5.8 | |
| 1,821.0 | 29,355.5 | 3,012.0 | -57.0 | 5.8 | -1.2 | -- | 6.7 |
5 min read•By Rajan Gulati
Mid caps that are thriving on growth & value
6 min read•By Rajan Gulati
We try to generate 20 per cent returns
2 min read•By Value Research
3 min read•By Mohammed Ekramul Haque
2 min read•By Mohammed Ekramul Haque
Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology,... ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. The company was founded in 1907 and is headquartered in Vadodara, India. Read more
Incorporated
2010
Chairman
Chirayu Amin
Managing Director
Shaunak Amin
Group
Alembic
Headquarters
Vadodara, Gujarat
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Alembic Pharmaceuticals Ltd stood at ₹ 7,875 Cr as on 31-Mar-25
The share price of Alembic Pharmaceuticals Ltd is ₹1,025.40 (NSE) and ₹1,023.80 (BSE) as of 16-Jul-2025 15:53 IST. Alembic Pharmaceuticals Ltd has given a return of 13.39% in the last 3 years.
Alembic Pharmaceuticals Ltd has a market capitalisation of ₹ 20,201 Cr as on 16-Jul-2025. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Alembic Pharmaceuticals Ltd is 3.89 times as on 16-Jul-2025, a 1% discount to its peers’ median range of 3.93 times.
The P/E ratio of Alembic Pharmaceuticals Ltd is 34.62 times as on 16-Jul-2025, a 8% discount to its peers’ median range of 37.67 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Alembic Pharmaceuticals Ltd and enter the required number of quantities and click on buy to purchase the shares of Alembic Pharmaceuticals Ltd.
Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. The company was founded in 1907 and is headquartered in Vadodara, India.
The prominent promoters of Alembic Pharmaceuticals Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
Nirayu Limited |
35.64%
|
|
Alembic Limited |
28.54%
|
|
Chirayu Ramanbhai Amin |
2.13%
|
The chairman of the company is Chirayu Amin, and the managing director is Shaunak Amin.
There is no promoter pledging in Alembic Pharmaceuticals Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
61,564
|
|
|
42,689
|
|
|
39,095
|
|
|
28,545
|
|
|
26,705
|
|
|
25,208
|
|
|
18,590
|
|
|
17,226
|
|
|
11,378
|
| Alembic Pharmaceuticals Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
11.63
|
|
Operating margin(%)
|
10.86
|
|
Net Margin(%)
|
8.66
|
|
Dividend yield(%)
|
1.18
|
Yes, TTM profit after tax of Alembic Pharmaceuticals Ltd was ₹582 Cr.
₹-5.10
(
